drugset / Trial / NCT00770913

Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis

NCT00770913

Phase 2/3 Completed 337 enrolled Eisai Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of E3810 tablets in patients with Proton Pump Inhibitor-resistant reflux esophagitis.

Timeline

Start
2008-10
Primary completion
2009-11
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Rabeprazole Small molecule 10 mg Oral
Subject Rabeprazole Small molecule 20 mg Oral

Indications